Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRL-103 in β-thalassemia Major
NCT05442346Phase 2Suspended
- Sponsor
- BRL Medicine Inc.
- Start
- Dec 2023
- Primary completion
- Sep 2024
- Modality
- Gene Editing, Gene Silencing, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of BRL-103 in beta thalassemia, sponsored by BRL Medicine Inc.. Started Dec 2023; status: suspended.
02
Drugs
BRL-103
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT05442346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442346.